Amylyx Pharmaceuticals (AMLX) Total Liabilities (2021 - 2026)

Amylyx Pharmaceuticals' Total Liabilities history runs 6 years deep, the most recent figure standing at $20.4 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 11.96% year-over-year to $20.4 million; the TTM figure through Mar 2026 stood at $20.4 million (up 11.96% YoY), while the FY2025 annual figure was $27.4 million, down 5.14% from the prior year.
• Total Liabilities was $20.4 million for Q1 2026 at Amylyx Pharmaceuticals, down from $27.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $93.0 million in Q1 2024 to a low of $18.3 million in Q1 2025.
• Historically, Total Liabilities has averaged $45.9 million across 5 years, with a median of $37.4 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities soared 191.7% in 2022, then tumbled 80.37% in 2025.
• A 5-year view of Total Liabilities shows it stood at $50.8 million in 2022, then surged by 65.25% to $84.0 million in 2023, then tumbled by 65.64% to $28.9 million in 2024, then retreated by 5.14% to $27.4 million in 2025, then declined by 25.36% to $20.4 million in 2026.
• The last three Total Liabilities figures came in at $20.4 million (Q1 2026), $27.4 million (Q4 2025), and $30.7 million (Q3 2025), per Business Quant data.